Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB
Open Access
- 25 March 2022
- journal article
- research article
- Published by Taylor & Francis in Bioengineered
- Vol. 13 (4) , 8881-8892
Abstract
MicroRNAs (miRNAs) are involved in various processes from the initiation and development of cancers, including chronic myeloid leukemia (CML). In this report, we aimed to investigate the roles of miR-23a in the regulation of imatinib mesylate (IM) sensitivity in CML cells and the possible mechanisms involved in this process. We demonstrated that the expression of miR-23a was markedly low in bone marrow mononuclear cells from patients in whom IM treatment had failed and imatinib-resistant K562/G01 cells when compared to patients with optimal responses and imatinib-sensitive K562 cells, respectively. Overexpression of miR-23a was shown to induce apoptosis of K562/G01 cells and sensitize these cells to imatinib treatment. With the aid of bioinformatics analysis, we revealed that CRYAB could be a potential downstream effector of miR-23a, contributing to miR-23a-mediated IM resistance. We also observed that the expression of CRYAB was inversely correlated with miR-23a expression in CML cell lines and patient samples. Importantly, chidamide upregulated miR-23a expression and reversed the IM resistance of CML cells. Together, these findings strongly suggest that miR-23a acts as a tumor suppressor by downregulating CRYAB expression. Restoration of miR-23a by chidamide may therefore have a therapeutic effect in controlling the sensitivity of CML cells to imatinib. Graphical abstractKeywords
This publication has 34 references indexed in Scilit:
- miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through TwistOncology Reports, 2014
- The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemiaCancer Gene Therapy, 2014
- Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinomaBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2014
- MicroRNAs in cancer: biomarkers, functions and therapyTrends in Molecular Medicine, 2014
- Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBlood, 2014
- MicroRNA-23a Antisense Enhances 5-Fluorouracil Chemosensitivity Through APAF-1/Caspase-9 Apoptotic Pathway in Colorectal Cancer CellsJournal of Cellular Biochemistry, 2013
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- Imatinib for Chronic Myeloid Leukemia: The Impact of Its Effectiveness and Long-term Side EffectsJNCI: Journal of the National Cancer Institute, 2011
- αB Crystallin Is Apically Secreted within Exosomes by Polarized Human Retinal Pigment Epithelium and Provides Neuroprotection to Adjacent CellsPLOS ONE, 2010
- MicroRNAs modulate the chemosensitivity of tumor cellsMolecular Cancer Therapeutics, 2008